Evaluation of FGFR Alteration Status in Urothelial Tumors

Methods Mol Biol. 2023:2684:283-291. doi: 10.1007/978-1-0716-3291-8_17.

Abstract

FGFR alterations in urothelial carcinoma are key driver alterations of tumorigenesis and are long recognized. In 2019 the Food and Drug Administration (FDA) approved the first pan-FGFR inhibitor, as the first specific targeted therapy in urothelial carcinoma. To receive the drug, alteration testing is required, and only alteration carriers can profit of this new agent. Due to this clinical need of detection and analysis of FGFR, here we describe two distinct and specific analytical methodologies: the SNaPshot analysis of nine FGFR3 point mutations and the QIAGEN therascreen® FGFR RGQ RT-PCR Kit, the FDA-approved companion diagnostic kit.

Keywords: FGFR testing; Inhibitor; QIAGEN therascreen® FGFR RGQ RT-PCR Kit; SNaPshot analysis; Targeted therapy; Urothelial carcinoma.

MeSH terms

  • Carcinoma, Transitional Cell* / drug therapy
  • Carcinoma, Transitional Cell* / genetics
  • Humans
  • Point Mutation
  • Protein Kinase Inhibitors / therapeutic use
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / genetics
  • Urologic Neoplasms* / drug therapy
  • Urologic Neoplasms* / genetics

Substances

  • Protein Kinase Inhibitors